A clinical trial update involving angiotensin II was recorded on August 19, 2026. The trial, registered as NCT04715568 and titled "Secondhand Tobacco Smoke and Cardiovascular Disease," is listed as a Phase 4 study. Its current status is recruiting, according to the ClinicalTrials.gov record.
Angiotensin II is an approved compound and appears in this trial's registration data. The listing does not include results or outcome data at this stage. No efficacy or safety findings have been reported for this study as of the update date.
The trial's recruiting status indicates that participant enrollment is ongoing rather than complete. Details on trial design, participant criteria, and endpoints can be found in the full registration record. As with all trial updates, status designations reflect administrative progress rather than clinical conclusions.
Readers interested in additional background can consult the compound overview for more context on angiotensin II.